Redeye comments on the clinical data from the SESAR study and the confusion it brought.
Redeye comments on the reverse split and new conditions of TO12.
Redeye leaves a comment following Magle’s announcement of a randomized controlled multicenter trial ...
Q-linea’s recent progress in extending the commercial network, establishing a pipeline of ASTar eval...
FDA's final minutes confirm that Orviglance is on track for NDA submission by mid-2025.
EBITA margin above 6% No more than 1.5x Net debt/EBITDA RTM Dividend at ~30% of net profit Ambitiou...
VBG Group visar fortsatt god lönsamhet trots en utmanande marknad.
Redeye comments on Dignitana’s takeover offer from Paxman, valued at SEK153m (SEK1.
Q4 figures slightly below ABGSCe Brage reserve uplift strengthens production outlook and valuation W...
Sprint Bioscience has secured 73.9% of a proposed SEK 31.
Intäkterna för den fjärde kvartalet uppgick till 0,6 (0,9) miljoner kronor.
Redeye endorses today’s news that Acarix was named the 2025 Digital Innovation Winner by the Global ...
Fiskars transitions to SaaS-based Direct-to-Consumer (DTC) services and takes EUR 27m impairment to ...
Q4: Headline figures pre-announced last week... ...
Atria will start planning an investment programme related to the production of convenience food at t...
12% EBITA margin target looks doable... ...more uncertainty on the 8% org.
Redeye gives a short comment on the positive outcome of Elicera’s TO2 warrant program.
Biovica records IVD test sales in Q3 of SEK 0.74m (460% above Q3 last year) and total sales of SEK 2...
Synthetic MR:s nettoomsättning i Q4-24 minskade med 58% till 12,6 MSEK, främst på grund av en långsa...
